G1 Therapeutics (GTHX)
(Real Time Quote from BATS)
$3.84 USD
-0.15 (-3.76%)
Updated Apr 25, 2024 11:31 AM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Brokerage Reports
0 items in cart
G1 Therapeutics [GTHX]
Reports for Purchase
Showing records 1 - 20 ( 348 total )
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
4Q23 Results; Cosela Sales Growth Trajectory Resumes; Important Data Readouts Later in 2024 Could Accelerate Growth
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
IDMC Recommends Continuing Pivotal Phase 3 PRESERVE 2 Trial to Final Overall Survival Analysis
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
1Q24 Preview; Time to Emerge from Winter PRESERVE
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
1Q24 Preview: Time to Emerge from Winter PRESERVE
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Long-Term Survival Results From Phase 2 Trial of Cosela in mTNBC Patients to Be Presented at 2023 SABCS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
3Q23 Results; Cosela Sales Lower Than Expected Due to the Continued Platinum Shortage
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology- 2023 Small Molecule Precision Oncology Review and Outlook
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Real-World Cosela Data Presented at ASCO Quality Care Symposium; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: G1 Therapeutics
Industry: Medical - Biomedical and Genetics
Real World Data Provides Real Support for Cosela in ES-SCLC; TNBC Next
Provider: Wedbush Securities Inc.
Analyst: Research Department